Spire Wealth Management’s GT Biopharma GTBP Stock Holding History

Spire Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-40	Closed	-$785	–	2327
2025 Q4	$785	Buy	+40	New	+$710	﹤0.01%	2226

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

INVST Indianapolis, Indiana $1.03B AUM 29.49% 1-Year Est. Return

Spire Wealth Management's GTBP Position: Q1 2026 in Review

Spire Wealth Management sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 40 shares — an estimated $785 sold.

Spire Wealth Management first reported a position in GTBP in Q4 2025 and held it in 1 quarter. The position peaked at $785 in Q4 2025. 40 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

Spire Wealth Management reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
Spire Wealth Management sold 40 GT Biopharma shares in Q1 2026, an estimated $785.
Spire Wealth Management first reported a position in GT Biopharma in Q4 2025 and held it in 1 quarter.
Spire Wealth Management's GT Biopharma position peaked at $785 in Q4 2025.
40 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Spire Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.